Guidelines for the management of cerebral vasospasm and DCI associated with aSAH: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Subarachnoid hemorrhage}} {{CMG}}; '''Associate Editor(s)-In-Chief:''' {{SaraM}} ==2012 AHA/ASA Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage...") |
No edit summary |
||
Line 5: | Line 5: | ||
====== | ===Management of Cerebral Vasospasm and DCI After aSAH: Recommendations=== | ||
{|class="wikitable" | {|class="wikitable" | ||
|- | |- | ||
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | | colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' Oral [[nimodipine]] should be administered to all patients with aSAH† ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' Maintenance of euvolemia and normal circulating blood volume is recommended to prevent [[DCI]] ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | ||
|- | |||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''3.''' Induction of hypertension is recommended for patients with [[DCI]] unless blood pressure is elevated at baseline or cardiac status precludes it ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |||
|} | |} | ||
†It should be noted that this agent has been shown to improve neuroogical outcomes but not cerebral vasospasm. The value of other calcium antagonists, whether administered orally or intravenously, remains uncertain. | |||
{|class="wikitable" | {|class="wikitable" | ||
|- | |- | ||
|colspan="1" style="text-align:center; background:LightCoral"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (Harm) | |colspan="1" style="text-align:center; background:LightCoral"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (Harm) | ||
|- | |- | ||
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' Prophylactic [[hypervolemia]] or [[balloon angioplasty]] before the development of angiographic spasm is not recommended ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | ||
|} | |} | ||
{|class="wikitable" | {|class="wikitable" | ||
Line 24: | Line 27: | ||
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | | colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | ||
|- | |- | ||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' | |bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' [[Transcranial Doppler]] is reasonable to monitor for the development of [[arterial vasospasm]] ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | ||
|- | |||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' [[Cerebral angioplasty]] and/or selective intra-arterial vasodilator therapy is reasonable in patients with symptomatic cerebral vasospasm, particularly those who are not rapidly responding to [[hypertensive therapy]] ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | |||
|} | |} | ||
Revision as of 00:19, 22 November 2016
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Sara Mehrsefat, M.D. [2]
2012 AHA/ASA Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage[1]
Management of Cerebral Vasospasm and DCI After aSAH: Recommendations
Class I |
"1. Oral nimodipine should be administered to all patients with aSAH† (Level of Evidence: A)" |
"2. Maintenance of euvolemia and normal circulating blood volume is recommended to prevent DCI (Level of Evidence: B)" |
"3. Induction of hypertension is recommended for patients with DCI unless blood pressure is elevated at baseline or cardiac status precludes it (Level of Evidence: B)" |
†It should be noted that this agent has been shown to improve neuroogical outcomes but not cerebral vasospasm. The value of other calcium antagonists, whether administered orally or intravenously, remains uncertain.
Class III (Harm) |
"1. Prophylactic hypervolemia or balloon angioplasty before the development of angiographic spasm is not recommended (Level of Evidence: B)" |
Class IIa |
"1. Transcranial Doppler is reasonable to monitor for the development of arterial vasospasm (Level of Evidence: B)" |
"2. Cerebral angioplasty and/or selective intra-arterial vasodilator therapy is reasonable in patients with symptomatic cerebral vasospasm, particularly those who are not rapidly responding to hypertensive therapy (Level of Evidence: B)" |
References
- ↑ Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage http://stroke.ahajournals.org/content/early/2012/05/03/STR.0b013e3182587839